Oral Communications and Posters
Vol. 5 No. s3 (2026): Abstracts of the XXIX National Congress of the Italian Society for the Study of Hemostasis and Thrombosis, 2026
https://doi.org/10.4081/btvb.2026.972

PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS

E. Marrone1, C. Arturo2, F. Cannavacciulo3, D. D’Ambrosio4, F. Gallucci1, M. Amitrano3, C. Di Gennaro2, P. Morella1, A. Maffettone5 | 1UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; 2UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; 3UOC Medicina Interna, AO Moscati, Avellino, Italy; 4UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; 5UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 26 October 2026
5
Views
2
Downloads

Authors

Emiliana Marrone
emilianamarrone@gmail.com
Premises and purpose of the study. Venous thromboembolism (VTE) is an important cause of morbidity and mortality among patients with cancer. According to recent guidelines its initial treatment may involve low-molecular-weight heparin (LMWH) or a direct oral anticoagulant (DOAC), as well as for long-term anticoagulation. Therefore, we conducted this Survey aimed at knowing aspects of the treatment of VTE in patients with cancer in the Campania Region.
Materials and methods. In December 2023, a questionnaire (Q) with 14 questions relating to the treatment of VTE in patients (pts) with cancer was sent to FADOI members in Campania. 55 pratictioners from 40 Internal Medicine Wards of Campania.
Results. The percentage of pts with cancer admitted in Internal Medicine ward presenting VTE: <25% (69%), 25-50%(31%). All pts with cancer and VTE begin anticoagulant treatment during hospidalitation. Its initial treatment is based on LMWH: all pts (29%), a small part 9%, most (62%), while on DOAC: all pts (11%), none (1.8%), a small part (52.7%), most 34.5%. Comorbidities in the 70% of the cases influence the choice of treatment. Mortality of this pts: <20% (42%), 20-40%(22%),41-60%(4%), unknown (32%). In the discharge letter of pts with cancer and VTE, LMWH are prescribed: <25% (45.5%), 25-50% (31%), 51-75% (9%), >75% (14.5%), while DOAC: <25% (11%), 25-50% (31%), 51-75% (16%), 75% (42%).
Conclusions. In Internal Medicine Wards of Campania LMWH is preferred over DOAC in initial treatment of VTE in pts with camcer, while for long-term anticoagulation DOAC is preferred over LMWH.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite



1.
Marrone E. PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS: E. Marrone1, C. Arturo2, F. Cannavacciulo3, D. D’Ambrosio4, F. Gallucci1, M. Amitrano3, C. Di Gennaro2, P. Morella1, A. Maffettone5 | 1UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; 2UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; 3UOC Medicina Interna, AO Moscati, Avellino, Italy; 4UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; 5UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy. Bleeding Thromb Vasc Biol [Internet]. 2026 Oct. 26 [cited 2026 Oct. 29];5(s3). Available from: https://www.btvb.org/btvb/article/view/972
Copyright (c) 2026 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.